Arcus Biosciences Community

NYSE:RCUS Community

1 Narratives written by author
0 Comments on narratives written by author
11 Fair Values set on narratives written by author

Arcus Biosciences

AN

AnalystConsensusTarget

Consensus Narrative from 11 Analysts

Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles

Key Takeaways Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market. Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.

US$32.55

FV

77.7% undervalued

-0.71%

Revenue growth p.a.

0

0

8

6 days ago